ECONOMIC DEVELOPMENT:
Can the FDA Get California's Biotech Sector Growing Again?Podcast: February 13, 2012
After two decades of steady job growth, employment in California's biomedical industry stalled while the state has struggled to recover from the deep global recession, according to the 2012 California Biomedical Industry Report from the California Healthcare Institute, BayBio, and PwC. We spoke to David Gollaher, CEO of the California Healthcare Institute, about the state of California’s biomedical industry, how companies are coping with the growing risk aversion of investors, and how the regulatory environment in the United States has both companies and investors turning away. Read More
Industrial/Ag Bio
- Developing Countries Lead Adoption Rate of Biotech Crops
Spurned by Europe and Japan, genetically modified crops are being embraced by the world’s small resource-poor farmers. Read More
Public Health
- Obama Administration Boosts Alzheimer’s Research Spending
Increase comes as research advocates brace for difficult budget fights. Read More
Research and Development
- GSK Boast: Improving R&D Productivity
Quarterly results, however, fall short of Wall Street’s expectations. Read More
Digital Health
- Yesterday’s Science Fiction, Tomorrow’s Reality
Israeli startup Check-Cap is developing an ingestible capsule that may help detect colorectal cancer. Read More
Business Strategy
- Siemens Seeks Growth in Companion Diagnostics
New partnerships with ViiV Healthcare and Tocagen are designed to strengthen Siemens’ competitive stance. Read More
Trials and Tribulations
- Astex Pharma Plummets after Advisory Panel Rejects the Use of Dacogen for Cancer
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More
Regulatory
- FDA Unveils Biosimilars Guidance
Draft guidelines reveal agency’s current thinking, solicit public comment. Read More
Deals
- Medical Device Firms Bring In the Bucks
Medical Device Firms Bring In the Bucks Read More
Healthcare Reform
- U.S. Lagging in Science and Technology Education
Study suggests a need to reform undergraduate science to add more STEM professionals. Read More
Commentary
- The Burrill Report (February 13, 2012): Can the FDA Get California's Biotech Sector Growing Again?
Listen to the latest edition from The Journal of Life Sciences. Browse all podcasts
February 2012
Download a free copy of the January 2012 issue of The Burrill Report. 2011—Year in Review
Click here to download.
Tomasz Sablinski, CEO of Transparency Life Sciences, discusses what’s broken in drug development today, what his company is doing to change traditional approaches, and what need to do to prove his company's use of crowdsourcing to better design cost-effective trials actually works.
Finance Scorecard
Filed IPOs
Completed IPOs
PDUFA Dates
Drug Approvals
Burrill Indices
Biggest Movers
The IPO market is heating up as social media giant Facebook filed for a $5 billion initial public offering and two more life sciences companies, Cempra and Greenway Medical Technologies, went public. Both companies, however, priced below their target ranges and raised less than they had hoped.
.jpg)
.gif)
.png){kind=small} |
 |